SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS 2003 Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41: 112.
  • 2
    U.S. Renal Data System 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.
  • 3
    U.S. Renal Data System 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.
  • 4
    Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, Puschett JB 1988 Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 67: 876881.
  • 5
    Reichel H, Deibert B, Schmidt-Gayk H, Ritz E 1991 Calcium metabolism in early chronic renal failure: Implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 6: 162169.
  • 6
    Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M 2005 Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 22052215.
  • 7
    Portale AA, Booth BE, Halloran BP, Morris RC Jr 1984 Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 73: 15801589.
  • 8
    Kawashima H, Kraut JA, Kurokawa K 1982 Metabolic acidosis suppresses 25-hydroxyvitamin in D3-1alpha-hydroxylase in the rat kidney. Distinct site and mechanism of action. J Clin Invest 70: 135140.
  • 9
    Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ 2004 Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 24: 503510.
  • 10
    Coen G, Mazzaferro S, Ballanti P, Sardella D, Chicca S, Manni M, Bonucci E, Taggi F 1996 Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: A cross-sectional study. Nephrol Dial Transplant 11: 813819.
  • 11
    Davies MR, Lund RJ, Mathew S, Hruska KA 2005 Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol 16: 917928.
  • 12
    Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB 2004 Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145: 30873094.
  • 13
    Dusso AS, Brown AJ, Slatopolsky E 2005 Vitamin D. Am J Physiol Renal Physiol 289: F8F28.
  • 14
    Panda DK, Miao D, Bolivar I, Li J, Huo R, Hendy GN, Goltzman D 2004 Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 279: 1675416766.
  • 15
    Vertino AM, Bula CM, Chen JR, Almeida M, Han L, Bellido T, Kousteni S, Norman AW, Manolagas SC 2005 Nongenotropic, anti-apoptotic signaling of 1alpha,25(OH)2-vitamin D3 and analogs through the ligand binding domain of the vitamin D receptor in osteoblasts and osteocytes. Mediation by Src, phosphatidylinositol 3-, and JNK kinases. J Biol Chem 280: 1413014137.
  • 16
    Kawaguchi H, Manabe N, Miyaura C, Chikuda H, Nakamura K, Kuro-o M, 1999 Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. J Clin Invest 104: 229239.
  • 17
    Mohammed S, Razzaque MS, Lanske B, 2006 Hypervitaminosis D and premature aging: Lessons learned from Fgf23 and Klotho mutant mice. Trends Mol Med 12: 300305.
  • 18
    Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, Josse S, Meyrier A, Lins RL, Fairey IT 1995 Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310: 358363.
  • 19
    Block GA, Hulbert-Shearon T, Levin N, Port F 1998 Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607617.
  • 20
    Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK 2001 Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12: 21312138.
  • 21
    Stack AG, Bloembergen WE 2001 A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis 38: 9921000.
  • 22
    Avram M, Mittman N, Myint M, Fein P 2001 Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 38: 13511357.
  • 23
    National Kidney Foundation 2003 K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: 1201.
  • 24
    Zisman AL, Hristova M, Ho LT, Sprague SM 2007 Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 27: 3643.
  • 25
    Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, Williams ME, Bishop CW 2004 Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 43: 877890.
  • 26
    Huraib S, Abu-Aisha H, Abed J, Al Wakeel J, Al Desouki M, Memon N 1997 Long-term effect of intravenous calcitriol on the treatment of severe hyperparathyroidism, parathyroid gland mass and bone mineral density in haemodialysis patients. Am J Nephrol 17: 118123.
  • 27
    Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM 2006 Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47: 263276.
  • 28
    Martinez I, Saracho R, Montenegro J, Llach F 1996 A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 11 (Suppl 3): 2228.
  • 29
    Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL 2005 Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520528.
  • 30
    Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL 2007 Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71: 3138.